The Surprising Reason Wealthy People Get Organ Transplants Faster
ORLANDO, Fla. (AP) -- You can't buy hearts, kidneys or other organs but money can still help you get one. Wealthy people are more likely to get on multiple waiting lists and score a transplant, and less likely to die while waiting for one, a new study finds. The work confirms what many have long suspected - the rich have advantages even in a system designed to steer organs to the sickest patients and those who have waited longest. Wealthier people can better afford the tests and travel to get on more than one transplant center's waiting list, and the new study shows how much this pays off. "Multiple-listed patients were more likely to get transplanted and less likely to die," said Dr. Raymond Givens at Columbia University Medical Center in New York. "It's a rational thing to do" from an individual patient's point of view, but it raises fairness questions, and the policy should be reconsidered, he said. He led the study and gave results Monday at an American Heart Association conference in Orlando. More than 122,000 Americans are wait-listed for an organ, including more than 100,000 who need kidneys. As of July, only 18,000 transplants have been done this year. The United Network for Organ Sharing, or UNOS, the agency that runs the nation's transplant system under a government contract, assigns organs based on a formula that considers medical urgency, tissue type, distance from the donor, time spent on the waiting list and other factors. UNOS has considered...
We report two cases in which fecal microbiota transplantation used for the treatment of recurrent Clostridium difficile infection were effective in eradicating colonization by carbapenemase-producing Enterobacteriaceae. The presented cases illustrate the potential benefit of fecal microbiota transplantation in resolution of asymptomatic carrier states of multiresistant microorganisms, suggesting the need for further investigations with a view to their applicability in this area.
ConclusionsIn a setting of short waiting list times, IABP can be used to bridge candidates to urgent HT with acceptable postoperative results, but there were significant rates of adverse clinical events during support.ResumenIntroducción y objetivosEn España, el balón de contrapulsación intraaórtico (BCIA) se ha usado frecuentemente como puente al trasplante cardiaco (TxC) urgente. El propósito es analizar los resultados de esta estrategia.MétodosSe realizó una revisión retrospectiva caso por caso de los registros clínicos de 281 pacientes adultos listad...
Warning for blood cancer patients who have undergone donor stem cell transplant
Conditions: Organ Transplant Rejection; Psoriasis Intervention: Drug: Sustained Release Injectable Tacrolimus Sponsors: Auritec Pharmaceuticals; National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Conditions: End Stage Renal Disease; Hepatitis C Intervention: Drug: 300mg glecaprevir/pibrentasivir 120mg Sponsor: Johns Hopkins University Not yet recruiting
Conditions: Kidney Failure; Liver Failure, Chronic; Kidney-Pancreas Failure Interventions: Drug: Custodiol-N Solution; Drug: Custodiol HTK Solution Sponsor: Dr. F. Köhler Chemie GmbH Not yet recruiting
The original version of this article contained a mistake in fig. 1a."Autologous HCT(n=111)" should be changed to"Allogeneic HCT (n=51)". Correct figure is presented below.
We report here on 22 APL patients treated with prolonged ATRA-ATO therapy at the time of disease relapse. Twenty patients obtained molecular complete remission (CRm) after 2 cycles (90%). Of these, two patients underwent hematopoietic stem cell transplant (HSCT) while the remaining proceeded to receive additional cycles (up to a total of 5) of ATRA-ATO. With a median follow-up of 58 months from the time of relapse (range: 21–128 months), the 4-year OS probability was 0.85 (95% CI 0.61–0.94), DFS was 0.74 (95% CI 0.49–0.88), and EFS 0.68 (95% CI 0.45–0.83). Two patients were resistant to A...
AbstractAutologous stem cell transplant (ASCT) is standard consolidation therapy in management of multiple myeloma (MM) patients. We reviewed records of all consecutive MM patients who underwent ASCT with high-dose melphalan at our center from year 2002 to 2016. A total of 141 ASCT were conducted (90 males and 51 females) with median age of 55 years (23–68 years). Median time from diagnosis to transplant was 7 months (3–79), with majority of patients underwent transplant in first remission, while 17 (12%) patients received transplant beyond first remission. Eighty-three percent patients obtained...
Jun Zhang, Zhi Sun, Zhenfeng Zhu, Jing Yang, Jian Kang, Guiwen Feng, Lin Zhou, Lihua Zuo, Yonggang Luo, Xiaojian Zhang
More News: Cardiology | Conferences | Contracts | Databases & Libraries | Government | Heart | Heart Failure | Heart Transplant | Hospitals | Huntington's Disease | Insurance | Internet | Jobs | Kidney Transplant | Kidney Transplantation | Liver | Liver Transplant | Lung Transplant | Medicaid | Medical Ethics | Organ Donation | Study | Transplant Surgery | Transplants | Urology & Nephrology | Websites